Practically Speaking: What is the Standard of Care for 1st Line mRCC?

To be added to the distribution list, please email: DDeCastro@southlakeregional.org

In this episode, Dr. Daniel Heng will help us understand when to use which treatment in first line mRCC.  With the new availability for Pembro/Lenvatnib what is the true standard of care now? 

Key Opinion Leader: 

Daniel Heng MD MPH FRCPC
Clinical Professor and Head, Medical Oncology, University of Calgary
Section Chief, Medical Oncology, Tom Baker Cancer Centre
Staff Medical Oncologist, Tom Baker Cancer Centre

Host:
Shaqil Kassam MD. MSc. FRCPC
skassam@southlakeregional.org
Medical Oncologist
Stronach Regional Cancer Centre, Newmarket, Ontario 

Outline:
0:00 - Introduction
1:50 – Dr. Daniel Heng Biography
2:40 - SOC in ITT, Intermediate/Poor, Favourable - is there a plateau
16:20 - Checkmate vs. Clear vs. Keynote - Comparisons 
18:20 - Special subgroups - Brain mets, Liver mets, different histologies, CPS/PDL1
22:50 - Progression post adjuvant I/O and 2nd line therapy decisions
26:45 - Pembro/Lenvatanib - Dosing 

Previous episodes: https://www.blogtalkradio.com/medoncnow